Trial Profile
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2015
Price :
$35
*
At a glance
- Drugs Ibalizumab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors TaiMed Biologics
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 May 2012 Planned end date changed from 1 Sep 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 30 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.